Q1 EPS Estimates for Cingulate Increased by Analyst

Key Points

• Ascendiant Capital Markets raised its Q1 2026 EPS estimate for Cingulate to ($0.38) (from ($0.64)), cut its FY2026 loss forecast to ($1.52) from ($2.54), and maintained a Buy rating with a $55 price objective.
• Despite the analyst revisions, Cingulate remains unprofitable (reported -$0.84 EPS on March 18 vs. -$0.56 expected), trades around $5.35 with a ~$62M market cap, and the consensus still implies deep losses (FY consensus -$11.69) with an average analyst target of $34.50.
• Insiders and some institutions have been buying—CEO and a director purchased shares in February and institutional ownership is about 41%—indicating insider confidence amid the mixed outlook.

Cingulate Inc. (NASDAQ:CING - Free Report) - Equities research analysts at Ascendiant Capital Markets increased their Q1 2026 earnings estimates for Cingulate in a research report issued to clients and investors on Tuesday, April 7th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.38) per share for the quarter, up from their prior forecast of ($0.64). Ascendiant Capital Markets has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Cingulate's current full-year earnings is ($11.69) per share. Ascendiant Capital Markets also issued estimates for Cingulate's Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.52) EPS and Q4 2027 earnings at ($0.32) EPS.

A number of other research analysts have also commented on the company. Roth Mkm cut their price target on Cingulate from $16.00 to $14.00 and set a "buy" rating for the company in a report on Monday, March 23rd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Cingulate in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $34.50.

Cingulate Stock Down 2.7%

Shares of CING stock opened at $5.35 on Wednesday. Cingulate has a 12 month low of $3.20 and a 12 month high of $11.89. The firm has a market cap of $62.22 million, a PE ratio of -1.24 and a beta of -0.76. The stock has a 50 day moving average of $6.75 and a 200-day moving average of $5.12. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.46.

Cingulate (NASDAQ:CING - Get Free Report) last released its quarterly earnings results on Wednesday, March 18th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28).

Institutional Trading of Cingulate

A number of institutional investors and hedge funds have recently modified their holdings of CING. XTX Topco Ltd bought a new stake in shares of Cingulate during the second quarter valued at approximately $45,000. Bank of America Corp DE increased its position in shares of Cingulate by 283.1% during the second quarter. Bank of America Corp DE now owns 7,501 shares of the company's stock valued at $31,000 after purchasing an additional 5,543 shares during the period. Quantum Private Wealth LLC increased its position in shares of Cingulate by 140.0% during the third quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company's stock valued at $94,000 after purchasing an additional 14,000 shares during the period. Soltis Investment Advisors LLC bought a new stake in shares of Cingulate during the fourth quarter valued at approximately $43,000. Finally, Geode Capital Management LLC increased its position in shares of Cingulate by 43.9% during the fourth quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock valued at $265,000 after purchasing an additional 18,629 shares during the period. 41.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Cingulate news, CEO Shane J. Schaffer purchased 6,809 shares of the business's stock in a transaction dated Friday, February 6th. The stock was bought at an average cost of $5.04 per share, for a total transaction of $34,317.36. Following the completion of the acquisition, the chief executive officer directly owned 10,175 shares in the company, valued at $51,282. This represents a 202.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter J. Werth acquired 19,455 shares of the stock in a transaction dated Friday, February 6th. The shares were purchased at an average price of $5.04 per share, for a total transaction of $98,053.20. Following the completion of the transaction, the director owned 117,449 shares of the company's stock, valued at $591,942.96. This trade represents a 19.85% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 33,074 shares of company stock valued at $166,693. Corporate insiders own 4.33% of the company's stock.

Cingulate News Roundup

Here are the key news stories impacting Cingulate this week:

• Positive Sentiment: Ascendiant materially trimmed expected losses for FY2026 (now -$1.52 vs prior -$2.54) and raised Q1–Q4 2026 quarter-level EPS forecasts to about ($0.38) — signals the firm expects operating improvement versus earlier views. MarketBeat Cingulate Coverage
• Positive Sentiment: The same shop lifted multiple 2026 quarter estimates (Q2–Q4 and Q3 specifically) and published 2027 quarter/FY forecasts (e.g., FY2027 -$1.39, Q4 2027 -$0.32) while maintaining a $55 price objective — consistent, broad upward revisions that support a constructive near‑term outlook. MarketBeat Cingulate Coverage
• Neutral Sentiment: Ascendiant's $55 target implies very large upside from current levels, which can attract speculators and momentum buyers but also reflects a long timeline and optimism that may be conditional on clinical/operational milestones. MarketBeat Cingulate Coverage
• Negative Sentiment: Offsetting the analyst optimism, Cingulate remains unprofitable (trailing negative EPS and a negative P/E), reported an EPS miss in mid‑March (reported -$0.84 vs. -$0.56 expected), and the street consensus still reflects deep losses (consensus FY at -$11.69) — fundamentals and small market cap increase risk if operational improvements slip. MarketBeat Cingulate Coverage

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.